Relmada Therapeutics (RLMD) 10-K 28 Sep 18 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2018	Sep. 28, 2018	Dec. 31, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	RELMADA THERAPEUTICS, INC.
Entity Central Index Key	1,553,643
Trading Symbol	RLMD
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Document Type	10-K
Document Period End Date	Jun. 30, 2018
Entity Emerging Growth Company	false
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,018
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Ex Transition Period	false
Entity Public Float			$ 9,408,840
Entity Common Stock, Shares Outstanding		12,549,870

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2018	Jun. 30, 2017
Current assets:
Cash and cash equivalents	$ 2,238,943	$ 1,710,512
Other receivable	7,617	232,597
Lease payments receivable - short term	64,486	59,319
Prepaid expenses	426,921	472,489
Total current assets	2,737,967	2,474,917
Fixed assets, net of accumulated depreciation	12,080	2,315
Other assets	24,788	21,961
Lease payments receivable - long term	273,244	337,730
Total assets	3,048,079	2,836,923
Current liabilities:
Accounts payable	765,439	529,558
Accrued expenses	659,455	394,558
Notes payable	285,170	276,670
Derivative liabilities	4,194,634	175,853
Total current liabilities	5,904,698	1,376,639
Promissory notes payable, net of discount of $4,548,543 and $0	2,656,457
Total liabilities	8,561,155	1,376,639
Commitments and contingencies
Stockholders' Equity (Deficit) :
Preferred stock value
Common stock, $0.001 par value, 100,000,000 shares authorized, 12,549,870 and 12,528,374 shares issued and outstanding, respectively	12,550	12,528
Additional paid-in capital	88,818,681	86,831,211
Accumulated deficit	(94,344,307)	(85,383,455)
Total stockholders' equity (deficit)	(5,513,076)	1,460,284
Total liabilities and stockholders' equity (deficit)	3,048,079	2,836,923
Class A convertible preferred stock
Stockholders' Equity (Deficit) :
Preferred stock value
Total stockholders' equity (deficit)

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2018	Jun. 30, 2017
Promissory notes payable, net of discount	$ 4,548,543	$ 0
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	200,000,000	200,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	12,549,870	12,528,374
Common stock, shares outstanding	12,549,870	12,528,374
Class A convertible preferred stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	3,500,000	3,500,000
Preferred stock, shares issued
Preferred stock, shares outstanding

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Operating expenses:
Research and development	$ 2,942,625	$ 1,293,498
General and administrative	3,974,850	5,925,335
Total operating expenses	6,917,475	7,218,833
Loss from operations	(6,917,475)	(7,218,833)
Other income (expenses):
Change in fair value of derivative liabilities	(708,901)	716,650
Interest expense, net	(1,336,826)	(550)
Sublease income	2,350	211,018
Gain on assignment of office lease		101,597
Loss on sales-type lease of fixed assets		(96,403)
Total other income (expenses)	(2,043,377)	932,312
Net loss	$ (8,960,852)	$ (6,286,521)
Net loss per common share - basic and diluted	$ (0.71)	$ (0.52)
Weighted average number of common shares outstanding - basic and diluted	12,545,342	12,074,244

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Jun. 30, 2016	$ 12,035	$ 86,127,252	$ (79,096,934)	$ 7,042,353
Balance, shares at Jun. 30, 2016	12,035,037
Issuance of restricted common stock	$ 6	(6)
Issuance of restricted common stock, shares	6,125
Stock-based compensation expense		704,452		704,452
Issuance of common stock for cashless exercises of warrants from consultants and Series A Preferred Stock warrant holder	$ 487	(487)
Issuance of common stock for cashless exercises of warrants from consultants and Series A Preferred Stock warrant holder, shares	487,212
Net loss			(6,286,521)	(6,286,521)
Balance at Jun. 30, 2017	$ 12,528	86,831,211	(85,383,455)	1,460,284
Balance, shares at Jun. 30, 2017	12,528,374
Issuance of restricted common stock	$ 4			4
Issuance of restricted common stock, shares	3,750
Stock-based compensation expense		517,999		517,999
Issuance of common stock for cashless exercises of warrants from consultants and Series A Preferred Stock warrant holder	$ 18	(18)
Issuance of common stock for cashless exercises of warrants from consultants and Series A Preferred Stock warrant holder, shares	17,746
Net loss			(8,960,852)	(8,960,852)
Issuance of warrants to promissory notes payable placement agent		200,658		200,658
Issuance of warrants to holders of promissory notes payable		1,268,831		1,268,831
Balance at Jun. 30, 2018	$ 12,550	$ 88,818,681	$ (94,344,307)	$ (5,513,076)
Balance, shares at Jun. 30, 2018	12,549,870

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities
Net loss	$ (8,960,852)	$ (6,286,521)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	2,627	85,271
Stock-based compensation	517,999	704,452
Amortization of deferred financing costs	1,029,183
Loss on sales-type lease of fixed assets		96,403
Gain on lease assignment		(101,597)
Change in fair value of derivative liabilities	708,901	(716,650)
Changes in operating assets and liabilities:
Prepaid expenses and other assets	42,741	370,333
Other receivable	224,980	(655)
Other assets	59,319	392,394
Accounts payable	157,392	(730,153)
Accrued expenses	215,632	(279,612)
Net cash used in operating activities	(6,002,078)	(6,466,335)
Cash flows from investing activities
Purchase of fixed assets	(12,391)	(49,690)
Net cash used in investing activities	(12,391)	(49,690)
Cash flows from financing activities
Proceeds from promissory notes and warrants, net of fees	6,534,400
Payment on notes payable	8,500	(273,670)
Net cash provided by (used in) financing activities	6,542,900	(273,670)
Net Increase (decrease) in cash and cash equivalents	528,431	(6,789,695)
Cash and cash equivalents at beginning of the year	1,710,512	8,500,207
Cash and cash equivalents at end of the year	2,238,943	1,710,512
Cash paid during the period for:
Income taxes
Interest	2,559	2,651
Non-cash investing and financing transactions:
Notes payable issued in connection with director and officer insurance policies	285,170	276,670
Derivative liabilities associated with issuance of promissory notes	3,309,880
Issuance of warrants to promissory notes payable placement agent	200,658
Issuance of warrants to holders of promissory notes payable	1,268,832
Cashless exercise of warrants for common stock	18	487
Issuance of restricted stock for service	4	6
Reclassification of long-term liabilities to accrued expense		$ 39,385

Business

Business	12 Months Ended
	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BUSINESS	NOTE 1 - BUSINESS Relmada Therapeutics, Inc. (“Relmada” or the “Company”) (a Nevada corporation), is a clinical-stage, publicly traded biotechnology company focused on the development of d-methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. d-methadone is a new chemical entity that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. REL-1017 is in Phase II for the treatment of major depressive disorder. In addition, the Company has a portfolio of three 505b2 product candidates at various stages of development. These products are: LevoCap ER (REL-1015), an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab (oral buprenorphine, REL-1028), an oral dosage form of the opioid analgesic buprenorphine; and MepiGel (topical mepivacaine, REL-1021), an orphan drug designated topical formulation of the local anesthetic mepivacaine. These products are not currently in active development. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s research and development will be successfully completed or that any product will be approved or commercially viable. The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with the FDA and other governmental regulations and approval requirements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The consolidated financial statements include the Company’s accounts and those of the Company’s wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation. Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the twelvemonth period following the issuance of these consolidated financial statements. As shown in the accompanying financial statements, the Company incurred negative operating cash flows of $6,002,078 for the year ended June 30, 2018 and accumulated losses of $94,344,307 from inception through June 30, 2018. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. We will need to raise additional funds in order to continue our clinical trials. Insufficient funds may cause us to delay, reduce the scope of or eliminate one or more of our development programs. Our future capital needs and the adequacy of our available funds will depend on many factors, including the cost of clinical studies and other actions needed to obtain regulatory approval of our products in development. Management plans to raise additional funds through public or private sales of equity or debt securities or from bank or other loans or through strategic collaboration and/or licensing agreements, to fund operations until the Company is able to generate enough revenues to cover operating costs. Financing may not be available on acceptable terms, or at all, and our failure to raise capital when needed could materially adversely impact our growth plans and our financial condition or results of operations. Additional equity financing, if available, may be dilutive to our shareholders. In addition, the Company may never be able to generate sufficient revenue if any from its potential products. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are the valuation of derivative liabilities, stock-based compensation expenses and recorded amounts related to income taxes. Cash and Cash Equivalents The Company considers cash deposits and all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company’s cash deposits are held at two high-credit-quality financial institutions. The Company’s cash deposits of $2,238,943 at June 30, 2018 at these institutions exceed federally insured limits. Patents Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain. Fixed Assets Fixed assets are stated at cost less accumulated depreciation. Fixed assets are comprised of computers and software, leasehold improvements, and furniture and fixtures. Depreciation is calculated using the straight-line method over the estimated useful life of the assets. Computers and software have an estimated useful life of three years. Furniture and fixtures have an estimated useful life of approximately seven years. Derivatives All derivatives are recorded at fair value on the balance sheet. The Company has determined fair values using market based pricing models incorporating readily available prices and or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity) that requires judgment and estimates. Fair Value of Financial Instruments The Company’s financial instruments primarily include cash, derivative liabilities and accounts payable. Due to the short-term nature of cash, other receivable and accounts payable the carrying amounts of these assets and liabilities approximate their fair value. Derivatives are recorded at fair value at each period end. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows: Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means. Level 3 Inputs - Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity). Fair Value on a Recurring Basis As required by Accounting Standard Codification (“ASC”) Topic No. 820 - 10 Fair Value Measurement The following table sets forth, by level within the fair value hierarchy, the Company’s financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2018: Quoted Prices In Active Significant Total Markets for Other Significant Carrying Identical Observable Unobservable Value as of Assets Inputs Inputs June 30, Description (Level 1) (Level 2) (Level 3) 2018 Derivative liability – warrant instruments $ - $ - $ 30,526 $ 30,526 Derivative liabilities – embedded redemption feature - - 4,164,108 4,164,108 $ - $ - $ 4,194,634 $ 4,194,634 The following table sets forth, by level within the fair value hierarchy, the Company’s financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2017: Description Quoted Prices Significant Significant Unobservable Inputs Total Carrying Value as of June 30, Derivative liabilities - warrant instruments $ - $ - $ 175,853 $ 175,853 The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as level 3 in the fair value hierarchy: Significant Unobservable Inputs Year Ended Year Ended Beginning balance $ 175,853 $ 892,503 Fair value of derivative liabilities from redemption feature of issued promissory notes payable 3,309,880 - Change in fair value of derivative liabilities included in net loss for the years ended June 30, 2018 and June 30, 2017 708,901 (716,650 ) Ending balance $ 4,194,634 $ 175,853 Income Taxes The Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future deductibility is uncertain. At June 30, 2018 and 2017, the Company had recorded a valuation allowance to the full extent of the Company’s net deferred tax assets since the likelihood of realization of the benefit does not meet the more likely than not threshold. The Company files a U.S. Federal income tax return and various state returns. Uncertain tax positions taken on our tax returns will be accounted for as liabilities for unrecognized tax benefits. The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in general and administrative expenses in the statements of operations. There were no liabilities recorded for uncertain tax positions at June 30, 2018 and 2017. The open tax years, subject to potential examination by the applicable taxing authority, for the Company are from June 30, 2015 through June 30, 2018. Research and Development Research and development costs primarily consist of research contracts for the advancement of product development, salaries and benefits, stock-based compensation, and consultants. The Company expenses all research and development costs in the period incurred. The Company makes an estimate of costs in relation to clinical study contracts. The Company analyzes the progress of studies, including the progress of clinical studies and phases, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Stock-Based Compensation The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which an employee is required to provide service in exchange for the award - the requisite service period. The grant-date fair value of employee share options is estimated using the Black-Scholes option pricing model adjusted for the unique characteristics of those instruments. Compensation expense for warrants granted to non-employees is determined by the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured, and is recognized over the service period. The expense is subsequently adjusted to fair value at the end of each reporting period until such warrants vest, and the fair value of such instruments, as adjusted, is expensed over the related vesting period. Adjustments to fair value at each reporting date may result in income or expense, depending upon the estimate of fair value and the amount of expense recorded prior to the adjustment. The Company reviews its agreements and the future performance obligation with respect to the unvested warrants for its vendors or consultants. When appropriate, the Company will expense the unvested warrants at the time when management deems the service obligation for future services has ceased. Net Loss per Common Share Basic net loss per common share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per common share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of Class A convertible preferred stock, Series A preferred stock, restricted stock awards, options and warrants to purchase common stock. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. Potentially dilutive securities are not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares): Year Ended Year Ended Common stock warrants 9,815,025 3,886,866 Restricted stock awards - 8,750 Common stock options 3,068,865 559,972 Total 12,883,890 4,455,588 Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), whereby lessees will be required to recognize for all leases at the commencement date a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. A modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements must be applied. The modified retrospective approach would not require any transition accounting for leases that expired before the earliest comparative period presented. Companies may not apply a full retrospective transition approach. ASU 2016-02 is effective for annual and interim periods beginning after December 15, 2018. Early application is permitted. The Company is currently evaluating the effects of this pronouncement on the consolidated financial statements. In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share Distinguishing Liabilities from Equity Derivatives and Hedging Accounting for Certain Financial Instruments with Down Round Features. In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting Subsequent Events The Company’s management reviewed all material events through the date the financial statements were issued for subsequent event disclosure consideration.

Other Receivable and Prepaid Ex

Other Receivable and Prepaid Expenses	12 Months Ended
	Jun. 30, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
OTHER RECEIVABLE AND PREPAID EXPENSES	NOTE 3 - OTHER RECEIVABLE AND PREPAID EXPENSES New York City allows investors and owners of emerging technology companies focused on biotechnology to claim a tax credit against the General Corporation Tax and Unincorporated Business Tax for amounts paid or incurred for certain facilities, operations, and employee training in New York City. The Company had other receivable of biotechnology tax credit from New York City of approximately $0 and $232,000 at June 20, 2018 and June 30, 2017 respectively. Prepaid expenses consisted of the following (rounded to nearest $00): June 30, June 30, Rent $ 9,200 $ 3,300 Research and development 20,800 9,600 Insurance 345,700 344,000 Legal 10,000 64,800 Other 41,200 50,800 Total $ 426,900 $ 472,500

Fixed Assets

Fixed Assets	12 Months Ended
	Jun. 30, 2018
Property, Plant and Equipment [Abstract]
FIXED ASSETS	NOTE 4 - FIXED ASSETS Fixed assets consisted of the following (rounded to nearest $00): Useful lives June 30, June 30, Computer and software 3 years $ 16,700 $ 4,300 Less: accumulated depreciation (4,600 ) (2,000 ) Fixed assets, net $ 12,100 $ 2,300 In June 2015, the Company entered into an Agreement of Lease (the “Lease”) for office space located at 275 Madison Avenue, 7th Floor, New York, New York 10016, its former corporate headquarter, with a third party. On March 10, 2016 and effective as of January 1, 2016, the Company entered into an Office Space License Agreement (the “License”) with Actinium Pharmaceuticals, Inc. (“Actinium”), with whom the Company shared two common board members until June 6, 2017, for the office space. The term of the License was three years from the effective date, with an automatic renewal provision. The cost of the License was approximately $16,600 per month for Actinium, subject to customary escalations and adjustments. The Company recorded the license fees as other income in the consolidated statements of operations. On June 6, 2017, the landlord and the Company agreed to assign the Lease for all of the office space to Actinium, pursuant to an Assignment and Consent Agreement. As of such date all rights, titles, and interest to the Lease, including related duties, liabilities, and obligations, were transferred from the Company to Actinium for a gain of approximately $100,000. On June 8, 2017, the Company entered into an Amended and Restated License Agreement with Actinium. Pursuant to the terms of the agreement, Actinium will continue to license the furniture, fixtures, equipment and tenant improvements located in the office (“FFE”) for a license fee of $7,529 per month until December 8, 2022. Actinium shall have at any time during the term of this agreement the right to purchase the FFE for $496,914, less any previously paid license fees. The license of FFE qualifies as a sales-type lease. At inception, the Company derecognized the underlying assets of $493,452, recognized discounted lease payments receivable of $397,049 using the discount rate of 8.38% and recognized loss on sales-type lease of fixed assets of $96,403. As of June 30, 2018, the balance of unearned interest income was approximately $68,800. The future minimum lease payments to be received under the lease for each of the fiscal years as of June 30 are as follows: 2019 90,348 2020 90,348 2021 90,348 2022 90,348 2023 45,174 Total $ 406,566

Accrued Expenses

Accrued Expenses	12 Months Ended
	Jun. 30, 2018
Payables and Accruals [Abstract]
ACCRUED EXPENSES	NOTE 5 - ACCRUED EXPENSES Accrued expenses consisted of the following (rounded to nearest $00): June 30, June 30, Research and development $ 10,400 $ - Professional fees 173,600 293,400 Interest on promissory notes 371,600 - Accrued vacation 48,000 56,900 Other 55,900 44,300 Total $ 659,500 $ 394,600

Notes Payable

Notes Payable	12 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 6 - NOTES PAYABLE In June 2018, the Company entered into a note for approximately $285,200 in conjunction with a renewal of its director and officer insurance policy. The interest rate was 2.35% per annum. The note matures on April 9, 2019. In June 2017, the Company entered into a note for approximately $276,700 in conjunction with a renewal of its director and officer insurance policy. The interest rate was 2.05% per annum. The note matured on April 9, 2018 and was repaid during the year ended June 30, 2018. At June 30, 2018 and 2017, the note payable outstanding balances were approximately $285,200 and $276,700, respectively.

Derivative Liabilities

Derivative Liabilities	12 Months Ended
	Jun. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE LIABILITIES	NOTE 7 - DERIVATIVE LIABILITIES ASC Topic No. 815 - Derivatives and Hedging The following is a summary of the assumptions used in the valuation model at June 30, 2018 and 2017: June 30, June 30, 2018 2017 Common stock issuable upon exercise of warrants 2,574,570 2,574,570 Market value of common stock on measurement date $ 1.01 $ 0.82 Exercise price $ 7.50 and $11.25 $ 7.50 and $11.25 Risk free interest rate (1) 2.33 % 1.38 % Expected life in years 0.95 1.95 Expected volatility (2) 102 % 106 % Expected dividend yields (3) None None (1) The risk-free interest rate was determined by management using the applicable Treasury Bill as of the measurement date. (2) The historical trading volatility was determined by calculating the volatility of the Company’s common stock. (3) The Company does not expect to pay a dividend in the foreseeable future. The Company has promissory notes with a redemption feature which is not clearly and closely related to the host instrument and therefore is considered an embedded derivative which was bifurcated and recorded as a derivative liability. In determining the fair value of the derivative liabilities, the Company used the Monte-Carlo pricing model. The assumptions used in the valuation model considers the probability of redemption, the length of time to maturity and value of the redemption feature. The following table sets forth, by level within the fair value hierarchy, the Company’s derivative liabilities that were accounted for at fair value on a recurring basis as of June 30, 2018: Balance at Initial valuation of derivative Increase (decrease) in fair value of derivative Fair value of derivatives Balance at 2017 period liabilities capital 2018 Series B warrants issued in connection with May and June 2014 offering $ 98,114 $ - $ (84,989 ) $ - $ 13,125 Placement Agent warrants issued in connection with May and June 2014 offering 77,739 - (60,338 ) - 17,401 Redemption feature of promissory notes 3,309,880 854,228 4,164,108 Total $ 175,853 $ 3,309,880 $ 708,901 $ - $ 4,194,634 The following table sets forth, by level within the fair value hierarchy, the Company’s derivative liabilities that were accounted for at fair value on a recurring basis as of June 30, 2017: Balance at Initial valuation of derivative Decrease in fair value of derivative Fair value of derivatives Balance at 2016 period liabilities capital 2017 Series B warrants issued in connection with May and June 2014 offering $ 504,482 $ - $ (406,368 ) $ - $ 98,114 Placement Agent warrants issued in connection with May and June 2014 offering 388,021 - (310,282 ) - 77,739 Total $ 892,503 $ - $ (716,650 ) $ - $ 175,853

Promissory Notes Payable

Promissory Notes Payable	12 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
PROMISSORY NOTES PAYABLE	NOTE 8 – PROMISSORY NOTES PAYABLE During the year ended June 30, 2018 the Company issued two year Convertible Promissory Notes, (the “Notes”) and warrants, for aggregate gross proceeds of $7,205,000, $6,534,400 net of direct debt issuance costs. The Notes are convertible at the option of the holder at any time prior to maturity into shares of the Company’s common stock at $0.75 per share. In addition, the Notes automatically convert at a discount upon the Company attaining an Equity Financing, as defined in the Note agreements. The warrants have a seven year term and are exercisable at $1.50 per share. The redemption features in the Notes is an embedded derivative which has been bifurcated and will be adjusted to fair value at each reporting period. In connection with the Notes, the Company incurred fees to the placement agent and other professionals. In addition, the placement agent received 804,000 warrants exercisable into the Company’s common stock at $1.65 per share. The warrants had an aggregate fair value of approximately $200,700 using the Black Scholes option pricing model. The fees were recorded as a reduction to the Notes and will be amortized over the term of the Notes as additional interest using the effective interest method.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Jun. 30, 2018
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	NOTE 9 – STOCKHOLDERS’ EQUITY Common Stock During the years ended June 30, 2018 and 2017, the Company issued 17,746 and 487,212 shares of common stock for cashless exercise of 17,770 and 487,707 warrants, respectively. During the years ended June 30, 2018 and 2017, the Company issued 3,750 and 6,125 shares of common stock for issuances of restricted common stocks, respectively. Options and warrants In December 2014, the Board of Directors adopted and the shareholders approved Relmada’s 2014 Stock Option and Equity Incentive Plan, as amended (the “Plan”), which allows for the granting of common stock awards, stock appreciation rights, and incentive and nonqualified stock options to purchase shares of the Company’s common stock to designated employees, non-employee directors, and consultants and advisors. The Plan allowed for the granting of 1,611,769 options or stock awards. In August 2015, the board approved an amendment to the Plan. Among other things, the Plan Amendment updates the definition of “change of control” and provides for accelerated vesting of all awards granted under the plan in the event of a change of control of the Company. In January 2017, the stockholders approved an increase of 2,500,000 shares to 4,111,769. In December 2017 the board approved, and in February 2018 the shareholders approved, an amendment to the Plan that increased the number of shares of Common Stock authorized for issuance under the Plan by an additional 2,500,000 shares from 4,111,768 to 6,611,768 The Company utilizes the Black-Scholes option pricing model to estimate the fair value of stock options and warrants. The price of common stock prior to the Company being public was determined from a third party valuation. The risk-free interest rate assumptions were based upon the observed interest rates appropriate for the expected term of the equity instruments. The expected dividend yield was assumed to be zero as the Company has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future. The expected volatility was based historical volatility. The Company routinely reviews its calculation of volatility changes in future volatility, the Company’s life cycle, its peer group, and other factors. The Company uses the simplified method for share-based compensation to estimate the expected term for employee option awards for share-based compensation in its option-pricing model. The Company uses the contractual term for non-employee options to estimate the expected term, for share-based compensation in its option-pricing model. On February 13, 2017, Mr. Michael Becker, the Company’s Chief Financial Officer, resigned and entered into a consulting agreement with the Company to provide financial, investor, digital media, and public relations services for the Company. As a result of Mr. Becker’s change from an employee to a consultant, his options and shares of restricted stock outstanding on such date continued to vest pursuant to the awards’ original terms and were reclassified as non-employee awards. On December 15, 2017 Mr. Becker’s consulting agreement expired and all unvested options were cancelled. Stock-based compensation - options During the year ended June 30, 2018, the Company granted various employees options to purchase a total of 2,650,000 shares of common stock. The options have a ten-year term and have an exercise price ranging from $0.80 to $0.88 per share. 2,450,000 options vest at a rate of 6.25% each quarter over 4 years, and 200,000 vest on the accomplishment of a clinical trial event. The fair value of the options on the grant date ranges from $0.65 to $0.71 per share using the Black-Scholes Option pricing model. The Company did not grant any options to employees during the year ended June 30, 2017. A summary of the changes in options outstanding for the year ended June 30, 2018 and 2017 is as follows: Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Outstanding and expected to vest at June 30, 2016 642,204 $ 6.41 7.7 $ 21,500 Forfeited (82,232 ) $ 6.41 - $ - Outstanding and expected to vest at June 30, 2017 559,972 $ 6.41 6.7 $ - Granted 2,650,000 $ 0.82 9.3 $ - Forfeited (141,107 ) $ 9.25 $ - Outstanding and expected to vest at June 30, 2018 3,068,865 $ 1.45 8.8 $ 511,000 Options exercisable at June 30, 2018 653,106 $ 3.47 7.0 $ 53,750 At June 30, 2018, the Company has unrecognized stock-based compensation expense of approximately $1,511,000 related to unvested stock options over the weighted average remaining service period of 3.1 years. The weighted average fair value of options granted during the years ended June 30, 2018 and 2017 was approximately $0.66 and $0.52 per share, respectively, on the date of grant using the Black-Scholes option pricing model with the following assumptions: Year Ended Year Ended Risk free interest rate 2.14 to 2.61 % 2.14 to 2.31 % Dividend yield 0 % 0 % Volatility 99.9-101.6 % 105.7 % Expected term (in years) 6.25 6.25 Stock-based compensation – restricted common stock A summary of the changes in outstanding restricted stocks during the years ended June 30, 2018 and 2017 is as follows: Number of Shares Weighted Average Fair Value Per Share Outstanding and expected to issue at June 30, 2016 20,375 $ 14.10 Issued (4,625 ) $ 14.91 Forfeited (7,000 ) $ 13.45 Outstanding and vested at June 30, 2017 8,750 $ 15.25 Issued (3,750 ) $ 15.25 Forfeited (5,000 ) $ 15.25 Outstanding and vested at June 30, 2018 - - The restricted stock grants vest over four years. The Company had an unrecognized expense at June 30, 2018 and 2017 of approximately $0 and $6,150, respectively, related to unvested restricted stock grants which will be recognized over the remaining weighted average service periods of 0 and 1.4years, respectively. During the year ended June 30, 2018 and 2017, the Company issued 3,750 and 4,625 shares, respectively, in relation to vested restricted stock. As of June 30, 2018, all restricted stock shares are issued. Stock-based compensation – warrants A summary of the changes in outstanding warrants during the years ended June 30, 2018 and 2017 is as follows: Number of Shares Weighted Average Exercise Price Per Share Outstanding and vested at June 30, 2016 4,224,573 $ 7.04 Issued 150,000 $ 1.64 Exercised (487,707 ) $ 0.001 Outstanding and vested at June 30, 2017 3,886,866 $ 7.71 Issued 5,945,929 $ 1.50 Exercised (17,770 ) $ 0.001 Outstanding and vested at June 30, 2018 9,815,025 $ 3.96 During the year ended June 30, 2017, the Company issued an aggregate of 150,000 warrants to a consultant for services rendered. The exercise price was determined based on the trading price of the Company’s common stock at warrant issuance date and range from $1.00 to $3.55 per share. The warrants are non-cancellable, vest upon issuance and expire the seventh anniversary of the date of issuance. The aggregate fair value of these warrants using the Black-Scholes option pricing model was $209,740 based on the following assumption: During the year ended June 30, 2018, the Company issued an aggregate of 338,600 warrants to a consultant for services rendered. The exercise price was determined on trading price of the Company’s common stock at warrant issuance date and range from $0.75 to $1.65 per share. The warrants are non-cancellable, vest upon issuance or over the service period and expire on the tenth or the seventh anniversary of the date of issuance. In addition, the Company issued an aggregate of 4,803,330 and 804,000 warrants to the holders of promissory notes payable and placement agent, respectively, during the year ended June 30, 2018. These warrants have exercise price from $1.50 to $1.65. The warrants are non-cancellable, vest upon issuance or over the service period and expire the seventh anniversary of the date of issuance The aggregate fair value of these warrants issued during the year ended June 30, 2018 using the Black-Scholes option pricing model was approximately $1,594,000 based on the following assumptions: Year Ended Risk free interest rate 2.13% to 2.86 % Dividend yield 0 % Volatility 83.7% to 99.4 % Expected term (in years) 6 to 10 At June 30, 2018 and 2017, the Company has $81,000 and $0 unrecognized stock based compensation expense related to outstanding warrants. At June 30, 2018 and 2017, the aggregate intrinsic value of warrants vested and outstanding was approximately $215,000 and $149,000, respectively. During the years ended June 30, 2018 and June 30, 2017, the Company recorded approximately $50,000 and $210,000 of expenses from issuances of warrants. Stock-based compensation by class of expense The following summarizes the components of stock-based compensation expense which includes common stock, stock options, warrants and restricted stock in the consolidated statements of operations for the years ended June 30, 2018 and 2017 (rounded to nearest $00) respectively: Year ended June 30, Year ended June 30, Research and development $ 62,500 $ 136,500 General and administrative 455,500 568,000 Total $ 518,000 $ 704,500

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2018
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 10 - RELATED PARTY TRANSACTIONS Advisory Firm On August 4, 2015, the Company entered into an Advisory and Consulting Agreement (the “Consulting Agreement”) with Sandesh Seth, the Company’s Chairman of the Board. The effective date of the Consulting Agreement is June 30, 2015. Mr. Seth has substantial experience in, among other matters, business development, corporate planning, corporate finance, strategic planning, investor relations and public relations, and an expansive network of connections spanning the biopharmaceutical industry, accounting, legal and corporate communications professions. Mr. Seth will provide advisory and consulting services to assist the Company with strategic advisory services, assist in prioritizing product development programs per strategic objectives, assist in recruiting of key personnel and directors, corporate planning, business development activities, corporate finance advice, and assist in investor and public relations services. In consideration for the services to be provided, the Company agreed to pay Mr. Seth $12,500 per month on an ongoing basis. On June 6, 2017, Mr. Seth resigned from the Company to focus his attention on matters external to Relmada. The Company agreed to continue its advisory and consulting arrangement with Mr. Seth until December 31, 2017. Consulting Agreement On June 12, 2017, the Company and Maged Shenouda, a director of the Company, entered into a Consulting Agreement. Pursuant to the terms of the agreement, Mr. Shenouda assisted the Company with matters requested by the Company. Mr. Shenouda was paid a consulting fee of $10,000 per month. The agreement was terminated effective December 31, 2017.

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2018
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 11 - INCOME TAXES No provision or benefit for federal or state income taxes has been recorded because the Company has incurred net losses for all periods presented and has recorded a valuation allowance against its deferred tax assets. The components of the Company’s deferred tax assets are as follows at: June 30, June 30, Deferred tax assets: Federal net operating loss $ 11,123,000 $ 15,425,000 State net operating loss 2,959,000 2,538,000 Stock-based compensation - 191,000 Research and development tax credits 1,081,000 925,000 Accruals 13,000 23,000 Other 37,000 65,000 Less: valuation allowance (15,213,000 ) (19,167,000 ) Total $ - $ - The Company has maintained a full valuation allowance against its deferred tax assets at June 30, 2018 and 2017. A valuation allowance is required to be recorded when it is more likely than not that some portion or all of the net deferred tax assets will not be realized. Since the Company cannot be assured of realizing the net deferred tax asset, a full valuation allowance has been provided. The valuation allowance (decreased)/increased for the years ended June 30, 2018 and 2017, by approximately ($3,954,000) and $4,650,000, respectively. At June 30, 2018 and 2017, the Company had federal and state net operating loss (NOL) carryforwards of approximately $52,967,000 and $45,470,000, respectively, which begin expiring in 2027 and 2032, respectively. The Company also has federal research and development tax credit carryforwards of approximately $1,081,000 that will begin to expire in 2028. The Company’s ability to use its NOL carryforwards may be limited if it experiences an “ownership change” as defined in Section 382 (“Section 382”) of the Internal Revenue Code of 1986, as amended. An ownership change generally occurs if certain stockholders increase their aggregate percentage ownership of a corporation’s stock by more than 50 percentage points over their lowest percentage ownership at any time during the testing period, which is generally the three-year period preceding any potential ownership change. The Company has not completed an analysis to determine whether any such limitations have been triggered as of June 30, 2018. A reconciliation of the statutory tax rate to the effective tax rate is as follows: Year Ended June 30, Year Ended June 30, Statutory federal income tax rate 27.5 % 34.0 % State (net of federal benefit) 6.0 % 6.0 % Non-deductible expenses (6.0 )% (0.75 )% Impact of Tax Cuts and Jobs Act (71.6 )% - Change in valuation allowance 44.1 % (39.25 )% Effective income tax rate 0 % 0 % The Company does not have any uncertain tax positions at June 30, 2018 and 2017 that would affect its effective tax rate. The Company does not anticipate a significant change in the amount of unrecognized tax benefits over the next twelve months. Because the Company is in a loss carryforward position, the Company is generally subject to US federal and state income tax examinations by tax authorities for all years for which a loss carryforward is available. If and when applicable, the Company will recognize interest and penalties as part of income tax expense. On December 22, 2017, the Tax Cuts and Jobs Act (“The Act”) was enacted into law. The Act provides for significant changes to the U.S. Internal Revenue Code of 1986 that impact corporate taxation requirements, such as the reduction of the federal tax rate for corporations from 34% to 21%. As a result of the Tax Act, deferred tax assets decreased by approximately $6,197,000, with an offsetting decrease to the valuation allowance.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 12 - COMMITMENTS AND CONTINGENCIES License Agreements Wonpung On August 20, 2007, the Company entered into a License Development and Commercialization Agreement with Wonpung Mulsan Co, a shareholder of the Company. Wonpung has exclusive territorial rights in countries it selects in Asia to market up to two drugs the Company is currently developing and a right of first refusal (“ROFR”) for up to an additional five drugs that the Company may develop in the future as defined in more detail in the license agreement. The Company received an upfront license fee of $1,500,000 and will earn royalties of up to 12% of net sales for up to two licensed products it is currently developing. The licensing terms for the ROFR products are subject to future negotiations and binding arbitration. The terms of each licensing agreement will expire on the earlier of any time from 15 years to 20 years after licensing or on the date of commercial availability of a generic product to such licensed product in the licensed territory. The Company’s current focus is on developing and marketing its products in the United States and not Asia. It will be several years before the Company markets its products in Asia. Third Party Licensor Based upon a prior acquisition, the Company assumed an obligation to pay a third party: (A) royalty payments up to 2% on net sales of licensed products that are not sold by sublicensee and (B) on each and every sublicense earned royalty payment received by licensee from its sublicensee on sales of license product by sublicensee, the higher of (i) 20% of the royalties received by licensee; or (ii) up to 2% of net sales of sublicensee. The Company will also make milestone payments of up to $4 or $2 million, for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and for the first commercial sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively. As of June 30, 2018, the Company has not generated any revenue related to this license agreement. Inturrisi / Manfredi In January 2018, we entered into an Intellectual Property Assignment Agreement (the “Assignment Agreement”) and License Agreement (the “License Agreement” and together with the Assignment Agreement, the “Agreements”) Leases In June 2015, the Company entered into a lease for its former corporate headquarter office. The lease expired in December 2023 and was subject to customary escalations and adjustments. On June 6, 2017, the landlord and the Company agreed to assign the Lease for all of the office space to Actinium. See Note 4. As of such date all rights, titles, and interest to the Lease, including related duties, liabilities, and obligations, were transferred from the Company to Actinium. Pursuant to the assignment of the lease, the Company derecognized its deferred rent liability and recorded gain on assignment of office lease of $101,597. The Company incurred rent expense of approximately $95,500, and $369,200 for the years ended June 30, 2018 and 2017, respectively. As of June 30, 2017, the Company changed its corporate headquarters to 750 Third Avenue, 9th Floor, New York, New York 10017 pursuant to a lease agreement with an initial monthly rent of $8,294. The lease contract periods are for 6 month periods. In November 2017 and May 2018, the Company renewed the lease for 6 month terms. The current lease expires on January 31, 2019, current monthly rent payments are $9,454. The Company leased an office in Pennsylvania for approximately $3,200 per month through September 2017. The Company entered into a sublease agreement through September 2016 whereby a tenant reimbursed the Company $2,350 for rent per month. Legal From time to time, the Company may become involved in lawsuits and other legal proceedings that arise in the course of business. Litigation is subject to inherent uncertainties, and it is not possible to predict the outcome of litigation with total confidence. Except as disclosed below, the Company is currently not aware of any legal proceedings or potential claims against it whose outcome would be likely, individually or in the aggregate, to have a material adverse effect on the Company’s business, financial condition, operating results, or cash flows. Lawsuit Brought by Former Officer In 2014, Relmada dismissed with prejudice its lawsuit against Najib Babul, which had sought to compel Dr. Babul, Relmada’s former President, to account for questionable expenditures of Relmada funds made while Babul controlled the Company. Relmada’s decision to end its claims was informed by the fact that Babul came forward with plausible explanations for some of the expenditures, and the fact that, because Babul was a former officer and director of Relmada being sued for his conduct in office, the Company was required to advance his expenses of the litigation; hence, Relmada was paying all the lawyers and consultants on both sides of the dispute. Relmada also agreed to reinstate certain stock purchase warrants in Babul’s name, which had been cancelled during the pendency of the litigation, and offered Babul the right to exchange his shares in Relmada Therapeutics, Inc. (a Delaware corporation and subsidiary of the Company) for shares in the Company. Babul has brought a second lawsuit against Relmada. Ruling on Relmada’s Motion to Dismiss, the United States District Court for the Eastern District of Pennsylvania dismissed Babul’s claims for breach of contract and intentional infliction of emotional distress, and left intact his claims for defamation, and wrongful use of civil process. Litigation is an inherently uncertain process, and there can be no assurances with respect to either the outcome or the consequences of this litigation. The Company recorded no contingent liability associated with litigation during the twelve months ended June 30, 2018.

Subsequent Events

Subsequent Events	12 Months Ended
	Jun. 30, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 13 - SUBSEQUENT EVENTS None.

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The consolidated financial statements include the Company’s accounts and those of the Company’s wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.
Going Concern	Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the twelvemonth period following the issuance of these consolidated financial statements. As shown in the accompanying financial statements, the Company incurred negative operating cash flows of $6,002,078 for the year ended June 30, 2018 and accumulated losses of $94,344,307 from inception through June 30, 2018. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. We will need to raise additional funds in order to continue our clinical trials. Insufficient funds may cause us to delay, reduce the scope of or eliminate one or more of our development programs. Our future capital needs and the adequacy of our available funds will depend on many factors, including the cost of clinical studies and other actions needed to obtain regulatory approval of our products in development. Management plans to raise additional funds through public or private sales of equity or debt securities or from bank or other loans or through strategic collaboration and/or licensing agreements, to fund operations until the Company is able to generate enough revenues to cover operating costs. Financing may not be available on acceptable terms, or at all, and our failure to raise capital when needed could materially adversely impact our growth plans and our financial condition or results of operations. Additional equity financing, if available, may be dilutive to our shareholders. In addition, the Company may never be able to generate sufficient revenue if any from its potential products.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are the valuation of derivative liabilities, stock-based compensation expenses and recorded amounts related to income taxes.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers cash deposits and all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company’s cash deposits are held at two high-credit-quality financial institutions. The Company’s cash deposits of $2,238,943 at June 30, 2018 at these institutions exceed federally insured limits.
Patents	Patents Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.
Fixed Assets	Fixed Assets Fixed assets are stated at cost less accumulated depreciation. Fixed assets are comprised of computers and software, leasehold improvements, and furniture and fixtures. Depreciation is calculated using the straight-line method over the estimated useful life of the assets. Computers and software have an estimated useful life of three years. Furniture and fixtures have an estimated useful life of approximately seven years.
Derivatives	Derivatives All derivatives are recorded at fair value on the balance sheet. The Company has determined fair values using market based pricing models incorporating readily available prices and or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity) that requires judgment and estimates.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s financial instruments primarily include cash, derivative liabilities and accounts payable. Due to the short-term nature of cash, other receivable and accounts payable the carrying amounts of these assets and liabilities approximate their fair value. Derivatives are recorded at fair value at each period end. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows: Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means. Level 3 Inputs - Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).
Fair Value on a Recurring Basis	Fair Value on a Recurring Basis As required by Accounting Standard Codification (“ASC”) Topic No. 820 - 10 Fair Value Measurement The following table sets forth, by level within the fair value hierarchy, the Company’s financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2018: Quoted Prices In Active Significant Total Markets for Other Significant Carrying Identical Observable Unobservable Value as of Assets Inputs Inputs June 30, Description (Level 1) (Level 2) (Level 3) 2018 Derivative liability – warrant instruments $ - $ - $ 30,526 $ 30,526 Derivative liabilities – embedded redemption feature - - 4,164,108 4,164,108 $ - $ - $ 4,194,634 $ 4,194,634 The following table sets forth, by level within the fair value hierarchy, the Company’s financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2017: Description Quoted Prices Significant Significant Unobservable Inputs Total Carrying Value as of June 30, Derivative liabilities - warrant instruments $ - $ - $ 175,853 $ 175,853 The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as level 3 in the fair value hierarchy: Significant Unobservable Inputs Year Ended Year Ended Beginning balance $ 175,853 $ 892,503 Fair value of derivative liabilities from redemption feature of issued promissory notes payable 3,309,880 - Change in fair value of derivative liabilities included in net loss for the years ended June 30, 2018 and June 30, 2017 708,901 (716,650 ) Ending balance $ 4,194,634 $ 175,853
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future deductibility is uncertain. At June 30, 2018 and 2017, the Company had recorded a valuation allowance to the full extent of the Company’s net deferred tax assets since the likelihood of realization of the benefit does not meet the more likely than not threshold. The Company files a U.S. Federal income tax return and various state returns. Uncertain tax positions taken on our tax returns will be accounted for as liabilities for unrecognized tax benefits. The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in general and administrative expenses in the statements of operations. There were no liabilities recorded for uncertain tax positions at June 30, 2018 and 2017. The open tax years, subject to potential examination by the applicable taxing authority, for the Company are from June 30, 2015 through June 30, 2018.
Research and Development	Research and Development Research and development costs primarily consist of research contracts for the advancement of product development, salaries and benefits, stock-based compensation, and consultants. The Company expenses all research and development costs in the period incurred. The Company makes an estimate of costs in relation to clinical study contracts. The Company analyzes the progress of studies, including the progress of clinical studies and phases, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability.
Stock-Based Compensation	Stock-Based Compensation The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which an employee is required to provide service in exchange for the award - the requisite service period. The grant-date fair value of employee share options is estimated using the Black-Scholes option pricing model adjusted for the unique characteristics of those instruments. Compensation expense for warrants granted to non-employees is determined by the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured, and is recognized over the service period. The expense is subsequently adjusted to fair value at the end of each reporting period until such warrants vest, and the fair value of such instruments, as adjusted, is expensed over the related vesting period. Adjustments to fair value at each reporting date may result in income or expense, depending upon the estimate of fair value and the amount of expense recorded prior to the adjustment. The Company reviews its agreements and the future performance obligation with respect to the unvested warrants for its vendors or consultants. When appropriate, the Company will expense the unvested warrants at the time when management deems the service obligation for future services has ceased.
Net Loss per Common Share	Net Loss per Common Share Basic net loss per common share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per common share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of Class A convertible preferred stock, Series A preferred stock, restricted stock awards, options and warrants to purchase common stock. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. Potentially dilutive securities are not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares): Year Ended Year Ended Common stock warrants 9,815,025 3,886,866 Restricted stock awards - 8,750 Common stock options 3,068,865 559,972 Total 12,883,890 4,455,588
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), whereby lessees will be required to recognize for all leases at the commencement date a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. A modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements must be applied. The modified retrospective approach would not require any transition accounting for leases that expired before the earliest comparative period presented. Companies may not apply a full retrospective transition approach. ASU 2016-02 is effective for annual and interim periods beginning after December 15, 2018. Early application is permitted. The Company is currently evaluating the effects of this pronouncement on the consolidated financial statements. In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share Distinguishing Liabilities from Equity Derivatives and Hedging Accounting for Certain Financial Instruments with Down Round Features. In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting
Subsequent Events	Subsequent Events The Company’s management reviewed all material events through the date the financial statements were issued for subsequent event disclosure consideration.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Schedule of fair value hierarchy, financial liabilities measured on recurring basis	The following table sets forth, by level within the fair value hierarchy, the Company’s financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2018: Quoted Prices In Active Significant Total Markets for Other Significant Carrying Identical Observable Unobservable Value as of Assets Inputs Inputs June 30, Description (Level 1) (Level 2) (Level 3) 2018 Derivative liability – warrant instruments $ - $ - $ 30,526 $ 30,526 Derivative liabilities – embedded redemption feature - - 4,164,108 4,164,108 $ - $ - $ 4,194,634 $ 4,194,634 The following table sets forth, by level within the fair value hierarchy, the Company’s financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2017: Description Quoted Prices Significant Significant Unobservable Inputs Total Carrying Value as of June 30, Derivative liabilities - warrant instruments $ - $ - $ 175,853 $ 175,853
Schedule of reconciliation of changes fair value of the company level three financial liabilities	The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as level 3 in the fair value hierarchy: Significant Unobservable Inputs Year Ended Year Ended Beginning balance $ 175,853 $ 892,503 Fair value of derivative liabilities from redemption feature of issued promissory notes payable 3,309,880 - Change in fair value of derivative liabilities included in net loss for the years ended June 30, 2018 and June 30, 2017 708,901 (716,650 ) Ending balance $ 4,194,634 $ 175,853
Schedule of anti-dilutive securities	Year Ended Year Ended Common stock warrants 9,815,025 3,886,866 Restricted stock awards - 8,750 Common stock options 3,068,865 559,972 Total 12,883,890 4,455,588

Other Receivable and Prepaid 22

Other Receivable and Prepaid Expenses (Tables)	12 Months Ended
	Jun. 30, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of prepaid expenses	June 30, June 30, Rent $ 9,200 $ 3,300 Research and development 20,800 9,600 Insurance 345,700 344,000 Legal 10,000 64,800 Other 41,200 50,800 Total $ 426,900 $ 472,500

Fixed Assets (Tables)

Fixed Assets (Tables)	12 Months Ended
	Jun. 30, 2018
Property, Plant and Equipment [Abstract]
Schedule of fixed assets, net of accumulated depreciation	Useful lives June 30, June 30, Computer and software 3 years $ 16,700 $ 4,300 Less: accumulated depreciation (4,600 ) (2,000 ) Fixed assets, net $ 12,100 $ 2,300
Schedule of future minimum lease payments to be received	2019 90,348 2020 90,348 2021 90,348 2022 90,348 2023 45,174 Total $ 406,566

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Jun. 30, 2018
Payables and Accruals [Abstract]
Schedule of accrued expenses	June 30, June 30, Research and development $ 10,400 $ - Professional fees 173,600 293,400 Interest on promissory notes 371,600 - Accrued vacation 48,000 56,900 Other 55,900 44,300 Total $ 659,500 $ 394,600

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	12 Months Ended
	Jun. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of assumptions used in valuation model	June 30, June 30, 2018 2017 Common stock issuable upon exercise of warrants 2,574,570 2,574,570 Market value of common stock on measurement date $ 1.01 $ 0.82 Exercise price $ 7.50 and $11.25 $ 7.50 and $11.25 Risk free interest rate (1) 2.33 % 1.38 % Expected life in years 0.95 1.95 Expected volatility (2) 102 % 106 % Expected dividend yields (3) None None (1) The risk-free interest rate was determined by management using the applicable Treasury Bill as of the measurement date. (2) The historical trading volatility was determined by calculating the volatility of the Company’s common stock. (3) The Company does not expect to pay a dividend in the foreseeable future.
Schedule of fair value of derivative liabilities	The following table sets forth, by level within the fair value hierarchy, the Company’s derivative liabilities that were accounted for at fair value on a recurring basis as of June 30, 2018: Balance at Initial valuation of derivative Increase (decrease) in fair value of derivative Fair value of derivatives Balance at 2017 period liabilities capital 2018 Series B warrants issued in connection with May and June 2014 offering $ 98,114 $ - $ (84,989 ) $ - $ 13,125 Placement Agent warrants issued in connection with May and June 2014 offering 77,739 - (60,338 ) - 17,401 Redemption feature of promissory notes 3,309,880 854,228 4,164,108 Total $ 175,853 $ 3,309,880 $ 708,901 $ - $ 4,194,634 The following table sets forth, by level within the fair value hierarchy, the Company’s derivative liabilities that were accounted for at fair value on a recurring basis as of June 30, 2017: Balance at Initial valuation of derivative Decrease in fair value of derivative Fair value of derivatives Balance at 2016 period liabilities capital 2017 Series B warrants issued in connection with May and June 2014 offering $ 504,482 $ - $ (406,368 ) $ - $ 98,114 Placement Agent warrants issued in connection with May and June 2014 offering 388,021 - (310,282 ) - 77,739 Total $ 892,503 $ - $ (716,650 ) $ - $ 175,853

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Jun. 30, 2018
Schedule of changes in options outstanding	Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Outstanding and expected to vest at June 30, 2016 642,204 $ 6.41 7.7 $ 21,500 Forfeited (82,232 ) $ 6.41 - $ - Outstanding and expected to vest at June 30, 2017 559,972 $ 6.41 6.7 $ - Granted 2,650,000 $ 0.82 9.3 $ - Forfeited (141,107 ) $ 9.25 $ - Outstanding and expected to vest at June 30, 2018 3,068,865 $ 1.45 8.8 $ 511,000 Options exercisable at June 30, 2018 653,106 $ 3.47 7.0 $ 53,750
Schedule of the changes in outstanding restricted stocks	Number of Shares Weighted Average Fair Value Per Share Outstanding and expected to issue at June 30, 2016 20,375 $ 14.10 Issued (4,625 ) $ 14.91 Forfeited (7,000 ) $ 13.45 Outstanding and vested at June 30, 2017 8,750 $ 15.25 Issued (3,750 ) $ 15.25 Forfeited (5,000 ) $ 15.25 Outstanding and vested at June 30, 2018 - -
Schedule of changes in outstanding warrants	Number of Shares Weighted Average Exercise Price Per Share Outstanding and vested at June 30, 2016 4,224,573 $ 7.04 Issued 150,000 $ 1.64 Exercised (487,707 ) $ 0.001 Outstanding and vested at June 30, 2017 3,886,866 $ 7.71 Issued 5,945,929 $ 1.50 Exercised (17,770 ) $ 0.001 Outstanding and vested at June 30, 2018 9,815,025 $ 3.96
Schedule of stock-based compensation expense	Year ended June 30, Year ended June 30, Research and development $ 62,500 $ 136,500 General and administrative 455,500 568,000 Total $ 518,000 $ 704,500
Stock options [Member]
Schedule of Black-Scholes option pricing model assumptions	Year Ended Year Ended Risk free interest rate 2.14 to 2.61 % 2.14 to 2.31 % Dividend yield 0 % 0 % Volatility 99.9-101.6 % 105.7 % Expected term (in years) 6.25 6.25
Warrants [Member]
Schedule of Black-Scholes option pricing model assumptions	Year Ended Risk free interest rate 2.13% to 2.86 % Dividend yield 0 % Volatility 83.7% to 99.4 % Expected term (in years) 6 to 10

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Schedule of deferred tax assets	June 30, June 30, Deferred tax assets: Federal net operating loss $ 11,123,000 $ 15,425,000 State net operating loss 2,959,000 2,538,000 Stock-based compensation - 191,000 Research and development tax credits 1,081,000 925,000 Accruals 13,000 23,000 Other 37,000 65,000 Less: valuation allowance (15,213,000 ) (19,167,000 ) Total $ - $ -
Schedule of reconciliation of the statutory tax rate to the effective tax rate	Year Ended June 30, Year Ended June 30, Statutory federal income tax rate 27.5 % 34.0 % State (net of federal benefit) 6.0 % 6.0 % Non-deductible expenses (6.0 )% (0.75 )% Impact of Tax Cuts and Jobs Act (71.6 )% - Change in valuation allowance 44.1 % (39.25 )% Effective income tax rate 0 % 0 %

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Details) - USD ($)	Jun. 30, 2018	Jun. 30, 2017
Schedule of fair value, financial liabilities measured on recurring basis
Derivative liabilities	$ 4,194,634	$ 175,853
Embedded redemption feature [Member]
Schedule of fair value, financial liabilities measured on recurring basis
Derivative liabilities	4,164,108
Warrant instruments [Member]
Schedule of fair value, financial liabilities measured on recurring basis
Derivative liabilities	30,526	175,853
Markets for Identical Assets (Level 1) [Member]
Schedule of fair value, financial liabilities measured on recurring basis
Derivative liabilities
Markets for Identical Assets (Level 1) [Member] | Embedded redemption feature [Member]
Schedule of fair value, financial liabilities measured on recurring basis
Derivative liabilities
Markets for Identical Assets (Level 1) [Member] | Warrant instruments [Member]
Schedule of fair value, financial liabilities measured on recurring basis
Derivative liabilities
Other Observable Inputs (Level 2) [Member]
Schedule of fair value, financial liabilities measured on recurring basis
Derivative liabilities
Other Observable Inputs (Level 2) [Member] | Embedded redemption feature [Member]
Schedule of fair value, financial liabilities measured on recurring basis
Derivative liabilities
Other Observable Inputs (Level 2) [Member] | Warrant instruments [Member]
Schedule of fair value, financial liabilities measured on recurring basis
Derivative liabilities
Significant Unobservable Inputs (Level 3) [Member]
Schedule of fair value, financial liabilities measured on recurring basis
Derivative liabilities	4,164,108
Significant Unobservable Inputs (Level 3) [Member] | Embedded redemption feature [Member]
Schedule of fair value, financial liabilities measured on recurring basis
Derivative liabilities	4,164,108
Significant Unobservable Inputs (Level 3) [Member] | Warrant instruments [Member]
Schedule of fair value, financial liabilities measured on recurring basis
Derivative liabilities	$ 30,526	$ 175,853

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Details 1) - Fair Value, Inputs, Level 3 [Member] - USD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
PROMISSORY NOTES PAYABLE [Line Items]
Beginning balance	$ 175,853	$ 892,503
Fair value of derivative liabilities from redemption feature of issued promissory notes payable	3,309,880
Change in fair value of derivative liabilities included in net loss for the years ended June 30, 2018 and June 30, 2017	708,901	(716,650)
Ending balance	$ 4,194,634	$ 175,853

Summary of Significant Accoun30

Summary of Significant Accounting Policies (Details 2) - shares	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Summary of anti-dilutive securities
Total	12,883,890	4,455,588
Common stock options [Member]
Summary of anti-dilutive securities
Total	3,068,865	559,972
Restricted stock awards [Member]
Summary of anti-dilutive securities
Total		8,750
Common stock warrants [Member]
Summary of anti-dilutive securities
Total	9,815,025	3,886,866

Summary of Significant Accoun31

Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Summary of Significant Accounting Policies (Textual)
Accumulated losses	$ (94,344,307)	$ (85,383,455)
Cash deposits amount	2,238,943
Operating cash flows	$ (6,002,078)	$ (6,466,335)
Computer and software [Member]
Summary of Significant Accounting Policies (Textual)
Fixed assets, estimated useful life	3 years
Furniture and Fixtures [Member]
Summary of Significant Accounting Policies (Textual)
Fixed assets, estimated useful life	7 years

Other Receivable and Prepaid 32

Other Receivable and Prepaid Expenses (Details) - USD ($)	Jun. 30, 2018	Jun. 30, 2017
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Rent	$ 9,200	$ 3,300
Research and development	20,800	9,600
Insurance	345,700	344,000
Legal	10,000	64,800
Other	41,200	50,800
Total	$ 426,900	$ 472,500

Other Receivable and Prepaid 33

Other Receivable and Prepaid Expenses (Details Textual) - USD ($)	Jun. 30, 2018	Jun. 30, 2017
Other Receivable and Prepaid Expenses (Textual)
Biotechnology tax credit receivable	$ 0	$ 232,000

Fixed Assets (Details)

Fixed Assets (Details) - USD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Computer and Software	$ 16,700	$ 4,300
Less: accumulated depreciation	(4,600)	(2,000)
Fixed assets, net	$ 12,080	$ 2,315
Computer and software [Member]
Useful lives	3 years

Fixed Assets (Details 1)

Fixed Assets (Details 1)	Jun. 30, 2018USD ($)
Property, Plant and Equipment [Abstract]
2,019	$ 90,348
2,020	90,348
2,021	90,348
2,022	90,348
2,023	45,174
Total	$ 406,566

Fixed Assets (Details Textual)

Fixed Assets (Details Textual) - USD ($)	Jun. 08, 2017	Jun. 06, 2017	Jun. 30, 2018
Fixed Assets (Textual)
Cost of License			$ 16,600
License Fee	$ 7,529
Discount rate of lease	8.38%
Gain of lease		$ 100,000
Term of license
Unearned interest income			$ 68,800
FFE [Member]
Fixed Assets (Textual)
Description of lease agreement	Actinium shall have at any time during the term of this agreement the right to purchase the FFE for $496,914, less any previously paid license fees. The license of FFE qualifies as a sales-type lease. At inception, the Company derecognized the underlying assets of $493,452, recognized discounted lease payments receivable of $397,049 using the discount rate of 8.38% and recognized loss on sales-type lease of fixed assets of $96,403.

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Jun. 30, 2018	Jun. 30, 2017
Payables and Accruals [Abstract]
Research and development	$ 10,400
Professional fees	173,600	293,400
Interest on Promissory Notes	371,600
Accrued vacation	48,000	56,900
Other	55,900	44,300
Total	$ 659,500	$ 394,600

Notes Payable (Details)

Notes Payable (Details) - USD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Notes Payable (Textual)
Note payable conjunction of director and officer	$ 285,200	$ 276,700
Note payable interest rate	2.35%	2.05%
Note payable outstanding	$ 285,200	$ 276,700
Note matures	Apr. 9, 2019	Apr. 9, 2018

Derivative Liabilities (Details

Derivative Liabilities (Details) - $ / shares	12 Months Ended
	Jun. 30, 2018		Jun. 30, 2017
Summary of assumptions used in valuation model of derivatives liabilities
Common stock issuable upon exercise of warrants	2,574,570		2,574,570
Market value of common stock on measurement date	$ 1.01		$ 0.82
Risk free interest rate	2.33%	[1]	1.38%
Expected life in years	11 months 12 days		1 year 11 months 12 days
Expected volatility	102.00%	[2]	106.00%
Expected dividend yields	0.00%	[3]	0.00%
Maximum [Member]
Summary of assumptions used in valuation model of derivatives liabilities
Exercise price	$ 11.25		$ 11.25
Minimum [Member]
Summary of assumptions used in valuation model of derivatives liabilities
Exercise price	$ 7.50		$ 7.50
[1]	The risk-free interest rate was determined by management using the applicable Treasury Bill as of the measurement date.
[2]	The historical trading volatility was determined by calculating the volatility of the Company's common stock.
[3]	The Company does not expect to pay a dividend in the foreseeable future.

Derivative Liabilities (Detai40

Derivative Liabilities (Details 1) - USD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Beginning balance	$ 175,853	$ 892,503
Initial valuation of derivative liabilities upon issuance of new warrants during the period	3,309,880
Increase (decrease) in fair value of derivative liabilities	708,901	(716,650)
Fair value of derivatives reclassified to additional paid-in-capital
Ending balance	4,194,634	175,853
Placement Agent warrants [Member]
Beginning balance	77,739	388,021
Initial valuation of derivative liabilities upon issuance of new warrants during the period
Increase (decrease) in fair value of derivative liabilities	(60,338)	(310,282)
Fair value of derivatives reclassified to additional paid-in-capital
Ending balance	17,401	77,739
Series B warrants [Member]
Beginning balance	98,114	504,482
Initial valuation of derivative liabilities upon issuance of new warrants during the period
Increase (decrease) in fair value of derivative liabilities	(84,989)	(406,368)
Fair value of derivatives reclassified to additional paid-in-capital
Ending balance	13,125	98,114
Redemption feature of promissory notes [Member]
Beginning balance
Initial valuation of derivative liabilities upon issuance of new warrants during the period	3,309,880
Increase (decrease) in fair value of derivative liabilities	854,228
Fair value of derivatives reclassified to additional paid-in-capital
Ending balance	$ 4,164,108

Promissory Notes Payable (Detai

Promissory Notes Payable (Details) - USD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Promissory Notes Payable (Textual)
Aggregate gross proceeds of convertible notes payable	$ 7,205,000
Common stock conversion price per share	$ 0.75
Term of warrants	7 years
Debt issuance costs, net	$ 6,534,400
Stock-based compensation - warrants [Member]
Promissory Notes Payable (Textual)
Warrants issued to placement agent, share	804,000
Warrants for aggregate proceeds	$ 1,594,000	$ 209,740
Aggregate fair value of warrants	$ 200,700

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Employee Stock Option [Member] - USD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding and expected to vest, Beginning balance	559,972	642,204
Number of Shares, Granted	2,650,000
Number of Shares, Forfeited	(141,107)	(82,232)
Number of Shares, Outstanding and expected to vest, Ending balance	3,068,865	559,972	642,204
Number of Shares, Options exercisable	653,106
Weighted Average Exercise Price Per Share, Outstanding and expected to vest - Beginning balance	$ 6.41	$ 6.41
Weighted Average Exercise Price Per Share, Granted	0.82
Weighted Average Exercise Price Per Share, Forfeited	9.25	6.41
Weighted Average Exercise Price Per Share, Outstanding and expected to vest - Ending balance	1.45	$ 6.41	$ 6.41
Weighted Average Exercise Price Per Share, Options exercisable	$ 3.47
Weighted Average Remaining Contractual Term (Years), Outstanding	8 years 9 months 18 days	6 years 8 months 12 days	7 years 26 days
Weighted Average Remaining Contractual Term (Years), Granted		9 years 3 months 19 days
Weighted Average Remaining Contractual Term (Years), Options exercisable	7 years
Aggregate Intrinsic Value, Outstanding and expected to vest - Beginning balance		$ 21,500
Aggregate Intrinsic Value, Outstanding and expected to vest - Ending balance	511,000		$ 21,500
Aggregate Intrinsic Value, Options exercisable	$ 53,750

Stockholders' Equity (Details 1

Stockholders' Equity (Details 1)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	0.00%	0.00%
Volatility		105.70%
Expected term (in years)	6 years 2 months 30 days	6 years 2 months 30 days
Minimum [Member] | Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	2.14%	2.14%
Volatility	99.90%
Maximum [Member] | Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	2.61%	2.31%
Volatility	101.60%
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%
Warrants [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	213.00%
Volatility	83.70%
Expected term (in years)	6 years
Warrants [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	286.00%
Volatility	99.40%
Expected term (in years)	10 years

Stockholders' Equity (Details 2

Stockholders' Equity (Details 2) - Restricted common stock [Member] - $ / shares	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Number of Shares, Outstanding and expected to vest, Beginning balance	8,750	20,375
Number of Shares, Issued	(3,750)	(4,625)
Number of Shares, Forfeited	(5,000)	(7,000)
Number of Shares, Outstanding and expected to vest, Ending balance		8,750
Weighted Average Fair Value Per Share, Outstanding and expected to vest, Beginning balance	$ 15.25	$ 14.10
Weighted Average Fair Value Per Share, Issued	15.25	14.91
Weighted Average Fair Value Per Share, Forfeited	15.25	13.45
Weighted Average Fair Value Per Share, Outstanding and expected to vest, Ending balance		$ 15.25

Stockholders' Equity (Details 3

Stockholders' Equity (Details 3) - Stock-based compensation - warrants [Member] - $ / shares	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding and vested, Beginning balance	3,886,866	4,224,573
Number of Shares, Issued	5,945,929	150,000
Number of Shares, Exercised	(17,770)	(487,707)
Number of Shares, Outstanding and vested, Ending balance	9,815,025	3,886,866
Weighted Average Exercise Price Per Share, Outstanding and vested, Beginning balance	$ 7.71	$ 7.04
Weighted Average Exercise Price Per Share, Issued	1.50	1.64
Weighted Average Exercise Price Per Share, Exercised	0.001	0.001
Weighted Average Exercise Price Per Share, Outstanding and vested, Ending balance	$ 3.96	$ 7.71

Stockholders' Equity (Details 4

Stockholders' Equity (Details 4) - USD ($)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 518,000	$ 704,500
Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	62,500	136,500
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 455,500	$ 568,000

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)	1 Months Ended			12 Months Ended
	Feb. 28, 2018	Jan. 31, 2017	Dec. 31, 2014	Jun. 30, 2018	Jun. 30, 2017
Stockholders' Equity (Textual)
Common stocks issued				17,746	487,212
Shares issued for cashless exercise of warrants				17,770	487,707
Common Stock
Stockholders' Equity (Textual)
Issuance of common stock for consulting services, shares				3,750	6,125
Common stock for issuances of restricted common stocks				3,750	6,125
Minimum [Member]
Stockholders' Equity (Textual)
Exercise price per share				$ 1.50
Maximum [Member]
Stockholders' Equity (Textual)
Exercise price per share				$ 1.65
Stock-based compensation - warrants [Member]
Stockholders' Equity (Textual)
Aggregate fair value of warrants issued				$ 1,594,000	$ 209,740
Issuance of common stock for consulting services, shares				338,600	150,000
Unrecognized stock-based compensation expense				$ 81,000	$ 0
Aggregate intrinsic value of warrants vested and outstanding				$ 215,000	149,000
Warrants issued to note holders				4,803,330
Warrants issued to placement agent, share				804,000
Expenses from issuances of warrants				$ 50,000	$ 210,000
Stock-based compensation - warrants [Member] | Minimum [Member]
Stockholders' Equity (Textual)
Exercise price per share				$ 0.75	$ 1
Stock-based compensation - warrants [Member] | Maximum [Member]
Stockholders' Equity (Textual)
Exercise price per share				$ 1.65	$ 3.55
Stock-based compensation - restricted common stock [Member]
Stockholders' Equity (Textual)
Unrecognized stock-based compensation expense				$ 0	$ 6,150
Recognized weighted average remaining service period				0 years	1 year 4 months 24 days
Vested shares to be issued				3,750	4,625
2014 Stock Option and Equity Incentive Plan [Member]
Stockholders' Equity (Textual)
Number of options granted		4,111,769	1,611,769
Stock options exercisable period				10 years
Number of shares available for future grants under stock option plan				3,505,279
Shares authorized to be issued	2,500,000	2,500,000
2014 Stock Option and Equity Incentive Plan [Member] | Minimum [Member]
Stockholders' Equity (Textual)
Number of options granted	4,111,768
2014 Stock Option and Equity Incentive Plan [Member] | Maximum [Member]
Stockholders' Equity (Textual)
Number of options granted	6,611,769
Stock-based Compensation - Options [Member]
Stockholders' Equity (Textual)
Number of options granted				2,650,000
Unrecognized stock-based compensation expense				$ 1,511,000
Unvested stock options weighted average remaining service period				3 years 1 month 6 days
Weighted average fair value of options granted				$ 0.82
Discount rate				0.00%	0.00%
Expected life term				6 years 2 months 30 days	6 years 2 months 30 days
Expected volatility rate					105.70%
Weighted average remaining service period				7 years
Options vested, description				2,450,000 options vest at a rate of 6.25% each quarter over 4 years, and 200,000 vest on the accomplishment of a clinical trial event. The fair value of the options on the grant date ranges from $0.65 to $0.71 per share using the Black-Scholes Option pricing model.
Stock-based Compensation - Options [Member] | Minimum [Member]
Stockholders' Equity (Textual)
Options exercise price				$ 0.80
Discount rate				2.14%	2.14%
Expected volatility rate				99.90%
Stock-based Compensation - Options [Member] | Maximum [Member]
Stockholders' Equity (Textual)
Options exercise price				$ 0.88
Discount rate				2.61%	2.31%
Expected volatility rate				101.60%

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	Jun. 12, 2017	Jun. 30, 2015
Related Party Transactions (Textual)
Consulting fee	$ 10,000
Mr. Seth [Member]
Related Party Transactions (Textual)
Advisory services fee		$ 12,500

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Jun. 30, 2018	Jun. 30, 2017
Deferred tax assets:
Federal net operating loss	$ 11,123,000	$ 15,425,000
State net operating loss	2,959,000	2,538,000
Stock-based compensation		191,000
Research and development tax credits	1,081,000	925,000
Accruals	13,000	23,000
Other	37,000	65,000
Less: valuation allowance	(15,213,000)	(19,167,000)
Total

Income Taxes (Details 1)

Income Taxes (Details 1)	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Statutory federal income tax rate	27.50%	34.00%
State (net of federal benefit)	6.00%	6.00%
Non-deductible expenses	(6.00%)	(0.75%)
Impact of Tax Cuts and Jobs Act	(71.60%)
Change in valuation allowance	44.10%	(39.25%)
Effective income tax rate	0.00%	0.00%

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 22, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Taxes (Textual)
Valuation allowance of deferred tax assets		$ (3,954,000)	$ 4,650,000
Federal and state net operating loss (NOL) carryforwards		$ 52,967,000	$ 45,470,000
Federal and state net operating loss carryforwards, expiring date		Jun. 30, 2027	Jun. 30, 2032
Federal tax credit carryforwards		$ 1,081,000
Tax credit carryforward, expiring date		Jun. 30, 2028
Federal tax rate		27.50%	34.00%
Deferred tax assets	$ 6,197,000
Minimum [Member]
Income Taxes (Textual)
Federal tax rate	21.00%
Maximum [Member]
Income Taxes (Textual)
Federal tax rate	34.00%

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	Sep. 30, 2017	Sep. 30, 2016	Aug. 20, 2007	Jun. 30, 2018	Jun. 30, 2017
Commitments and Contingencies (Textual)
Rent expense	$ 3,200			$ 95,500	$ 369,200
Lease expiration date				Dec. 31, 2023
Gain on assignment of office lease					$ 101,597
Sublease rent		$ 2,350
Licensing Agreements [Member]
Commitments and Contingencies (Textual)
Lease term, description				A lease agreement with an initial monthly rent of $8,294. The lease contract periods are for 6 month periods. In November 2017 and May 2018, the Company renewed the lease for 6 month terms. The current lease expires on January 31, 2019, current monthly rent payments are $9,454.
Licensing Agreements [Member] | Wonpung [Member]
Commitments and Contingencies (Textual)
Lease term, description			The terms of each licensing agreement will expire on the earlier of any time from 15 years to 20 years after licensing or on the date of commercial availability of a generic product to such licensed product in the licensed territory.
Upfront license fee			$ 1,500,000
Business acquisition, description			(A) royalty payments up to 2% on net sales of licensed products that are not sold by sublicensee and (B) on each and every sublicense earned royalty payment received by licensee from its sublicensee on sales of license product by sublicensee, the higher of (i) 20% of the royalties received by licensee; or (ii) up to 2% of net sales of sublicensee. The Company will also make milestone payments of up to $4 or $2 million, for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and for the first commercial sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively. As of June 30, 2018, the Company has not generated any revenue related to this license agreement.